This first International Alliance for Biological Standardization Covid-19 webinar brought together a broad range of international stakeholders, including academia, regulators, funders and industry, with a considerable delegation from low- and middle-income countries, to discuss the virology, epidemiology and immunology of, and the vaccine development for SARS-CoV-2. Highlights • In SARS-CoV-2, genetic diversity exists but has limited impact on antigenicity. • Second and possibly third SARS-CoV-2 waves are expected, only to be controlled with safe and effective vaccines. • Immunopathology plays a role in severe Covid-19, with a role for macrophages, T lymphocytes and potentially antibodies. • Normally taking many years, under the outbreak paradigm, the goal is to achieve vaccine development within 12–18 months.
【저자키워드】 immunology, SARS-CoV-2, Vaccine development, Virology, Epidemiology,